Depemokimab Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Depemokimab Growth

1. Market Share Gains and New Patient Starts

• Depemokimab is positioned to capture substantial share in severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) because it is an ultra-long-acting anti-IL-5 biologic administered twice yearly, simplifying treatment versus currently available more frequent dosing biologics.
• Phase III data show large and clinically meaningful reductions in exacerbations and nasal polyp size, so expectations for strong new-patient starts at launch are high, particularly among patients and clinicians seeking less frequent dosing.
• GSK's commercial planning (regulatory filings, payer engagement and specialist-center outreach) is set up to drive early adoption if regulators grant marketing approvals.

2. Expansion Across Key Indications

• Severe eosinophilic asthma: Depemokimab's SWIFT-1 and SWIFT-2 Phase III trials demonstrated ~54% reduction in annual severe exacerbation rate vs placebo in eosinophilic asthma-making asthma a primary commercial indication.
• Chronic rhinosinusitis with nasal polyps (CRSwNP): ANCHOR-1 and ANCHOR-2 Phase III trials met co-primary endpoints (reduced polyp score and nasal obstruction), supporting CRSwNP as another lead indication.
• Type-2 inflammatory comorbidity populations: Trial programs included patients with overlapping type-2 disease (e.g., asthma + CRSwNP), and pooled analyses showed improvements across multiple patient-reported and objective outcomes - enabling a multi-specialty commercialization approach (pulmonology, allergy, ENT).

3. Geographic Expansion

• GSK has submitted/received regulatory acceptances for review across major jurisdictions (FDA BLA acceptance, Health Canada review accepted), and is preparing filings/launch plans for the US, EU, Canada, Japan and other markets to enable broad global roll-out.
• The twice-yearly dosing profile is especially attractive in regions with access challenges or where injection-visit frequency limits uptake - Asia-Pacific and parts of Europe/Latin America are expected to be high-growth markets if reimbursement is secured.

4. New Indication Approvals (Regulatory status / expectations)

• As of the latest public updates, depemokimab has positive Phase III data for severe eosinophilic asthma (SWIFT studies) and CRSwNP (ANCHOR studies), and regulatory submissions/reviews are underway (e.g., FDA accepted for review; Health Canada accepted). Final approvals depend on agency review timelines and any requested follow-up analyses.
• If approved for both asthma and CRSwNP, depemokimab would broaden GSK's respiratory franchise and offer a differentiating dosing schedule (twice yearly) versus current anti-IL-5 and other type-2 biologics.

5. Strong Volume Momentum

• Large Phase III effect sizes (notably a >50% reduction in exacerbations in SWIFT and strong polyp shrinkage in ANCHOR) support forecasts for rapid uptake and strong prescription volumes within the eligible severe eosinophilic and CRSwNP populations.
• Safety and tolerability in the trials were consistent with the IL-5 class (mainly GI and injection-site effects reported as tolerable), supporting persistence/adherence advantages for a twice-yearly agent - a positive factor for real-world volume momentum.

6. Competitive Differentiation and Market Trends

• Ultra-long-acting, twice-yearly dosing is the core differentiation - offering major convenience and adherence benefits versus monthly or every-4-/8-week biologics, which may translate into market share gains.
• Mechanism: Targets IL-5 (key eosinophil survival/activation cytokine) with high potency and extended half-life-directly addressing a mechanistic driver of exacerbations and nasal polyp formation in type-2 disease.
• Market trends supporting uptake: rising focus on treating obesity and respiratory comorbidities is increasing specialist referrals; payers are receptive to therapies that reduce exacerbations/hospitalisations and cut overall cost of care - real-world evidence and health-economic modelling will be important in reimbursement discussions.
• Risks & headwinds: regulatory review outcomes/timelines, price & reimbursement negotiations, potential post-marketing safety surveillance needs for long-acting biologics, and intense competition from established anti-IL-5 agents and other biologic classes (IL-4/13, anti-IgE) are material factors that will influence ultimate market share.

Depemokimab Recent Developments

• In June 2025, Depemokimab, an ultra-long-acting IL-5-targeted monoclonal antibody, reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype, according to a report on the SWIFT studies. SWIFT-1 and SWIFT-2 were Phase IIIA, randomized, placebo-controlled replicate trials that compared the safety and efficacy of depemokimab with placebo in patients with severe asthma and an eosinophilic phenotype, characterized by high blood eosinophil counts (BECs; >= 300 cells/µL in the previous 12 months or >= 150 cells/µL at screening) and a history of exacerbations despite receiving medium- or high-dose inhaled glucocorticoids. The primary end point, the annualized rate of exacerbations, was met; depemokimab significantly reduced exacerbation rates in both studies. In SWIFT-1, the exacerbation rate was 0.46 with depemokimab vs 1.11 with placebo (rate ratio of 0.42); and in SWIFT-2, the exacerbation rate was 0.56 with depemokimab vs 1.08 with placebo (rate ratio of 0.52; P < .001) for both. There were similar adverse effects in both groups.
• In May 2025, GSK submitted a New Drug Submission (NDS) to Health Canada for Depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller. The second indication is as an add-on maintenance treatment of adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The NDS is based on data from the positive SWIFT and ANCHOR trials.
• In March 2025, GSK announced that the US Food and Drug Administration (FDA) accepted for review the Biologics License Application for the use of Depemokimab in two indications.

"Depemokimab Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Depemokimab for potential indications like Asthma, Rhinosinusitis, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, and Hypereosinophilic syndrome in the 7MM. A detailed picture of Depemokimab's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Depemokimab for potential indications. The Depemokimab market report provides insights about Depemokimab's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Depemokimab performance, future market assessments inclusive of the Depemokimab market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Depemokimab sales forecasts, along with factors driving its market.

Depemokimab Drug Summary

Depemokimab, a monoclonal antibody that targets IL-5, is the first ultra-long-acting biologic to be evaluated in Phase III trials. IL-5 is a key cytokine (protein) in type 2 inflammation. Type 2 inflammation is typically identified by blood eosinophil count and is an underlying driver in many diseases. This type of inflammation is present in the majority of patients with difficult to treat asthma and can lead to exacerbations and hospitalization. Type 2 inflammation is also present in up to 85% of people with CRSwNP and is associated with more severe disease and symptoms. With IL-5 inhibition, eosinophils are significantly reduced and there is evidence to show IL-5 has broader effects on other structural and immune cell types beyond eosinophils. The report provides Depemokimab's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Depemokimab is in the Registration phase for Asthma (NCT06979323) and Rhinosinusitis (NCT05281523), and in the Phase III stage of clinical development for the treatment of Chronic obstructive pulmonary disease (NCT07177339), Churg-Strauss syndrome (NCT05263934), and Hypereosinophilic syndrome (NCT05334368).

Scope of the Depemokimab Market Report

The report provides insights into:

• A comprehensive product overview including the Depemokimab MoA, description, dosage and administration, research and development activities in potential indications like Asthma, Rhinosinusitis, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, and Hypereosinophilic syndrome.
• Elaborated details on Depemokimab regulatory milestones and other development activities have been provided in Depemokimab market report.
• The report also highlights Depemokimab's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Depemokimab market report also covers the patents information, generic entry and impact on cost cut.
• The Depemokimab market report contains current and forecasted Depemokimab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Depemokimab market report also features the SWOT analysis with analyst views for Depemokimab in potential indications.

Methodology:

The Depemokimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Depemokimab Analytical Perspective by DelveInsight

• In-depth Depemokimab Market Assessment

This Depemokimab sales market forecast report provides a detailed market assessment of Depemokimab for potential indications like Asthma, Rhinosinusitis, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, and Hypereosinophilic syndromes in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Depemokimab sales data uptil 2034.

• Depemokimab Clinical Assessment

The Depemokimab market report provides the clinical trials information of Depemokimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Depemokimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Depemokimab Market Potential & Revenue Forecast

• Projected market size for the Depemokimab and its key indications
• Estimated Depemokimab sales potential (Depemokimab peak sales forecasts)
• Depemokimab Pricing strategies and reimbursement landscape

Depemokimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Depemokimab Market positioning compared to existing treatments
• Depemokimab Strengths & weaknesses relative to competitors

Depemokimab Regulatory & Commercial Milestones

• Depemokimab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Depemokimab Clinical Differentiation

• Depemokimab Efficacy & safety advantages over existing drugs
• Depemokimab Unique selling points

Depemokimab Market Report Highlights

• In the coming years, the Depemokimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Depemokimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Depemokimab's dominance.
• Other emerging products for Asthma, Rhinosinusitis, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, and Hypereosinophilic syndrome are expected to give tough market competition to Depemokimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Depemokimab in potential indications.
• Analyse Depemokimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Depemokimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Depemokimab in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Depemokimab? How strong is Depemokimab's clinical and commercial performance?
• What is Depemokimab's clinical trial status in each individual indications such as Asthma, Rhinosinusitis, Chronic obstructive pulmonary disease, Churg-Strauss syndrome, and Hypereosinophilic syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Depemokimab Manufacturers?
• What are the key designations that have been granted to Depemokimab for potential indications? How are they going to impact Depemokimab's penetration in various geographies?
• What is the current and forecasted Depemokimab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Depemokimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Depemokimab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Depemokimab? What is the duration of therapy and what are the geographical variations in cost per patient?